SY001

SY001 focuses on an undisclosed target X, a critical enzyme in DNA damage repair. The expression of X is scarce in normal cells, while is overexpressed in tumor cells. X shows synthetic lethality with BRCA1/2 mutations or homologous recombination defects. It may have promising therapeutic effects for a broad spectrum of tumors as a single agent or in combination with other chemotherapeutic drugs.